Prostate cancer incidence and mortality have consistently been higher in Black men than White men. Recent statistics from U.S. Surveillance, […]
New diagnostic tools to assess risk of metastasis, chemoresistance and relapse in patients with prostate cancer are needed because cancer […]
Detection options: MRI-targeted biopsy with ultrasound verses the 12 core approach.
Congratulations Drs. Jonathan Wisco, Rachel L. Flynn and Alla Grishok!
BRD4, a member of the BET bromodomain protein family, could be an important new target to prevent castration-resistant prostate cancer metastases.
From this Phase 2 trial result, it is reasonable to conclude that Stereotactic ablative radiotherapy (SABR) is a promising treatment approach for men with recurrent hormone-sensitive oligometastatic prostate cancer who wish to delay initiation of androgen deprivation therapy.
One of the important and emerging questions in cancer metastasis is: how does the primary prostate tumor engage in cellular […]
Researchers at Boston University School of Medicine (BUSM) have discovered that blocking a specific protein, may be a promising strategy […]
When concern arises that a man may have prostate cancer, the current recommendation is to perform an ultrasound (US) guided […]
Biochemical relapse is a challenging time for men with prostate cancer. We know it’s a time when the cancer is […]